Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Antibodies, Monoclonal"" wg kryterium: Temat


Tytuł:
Re-Engineering Therapeutic Anti-Aβ Monoclonal Antibody to Target Amyloid Light Chain.
Autorzy:
Bai J; Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China.
Li X; Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China.
Zhao J; Cancer and Inflammation Program, National Cancer Institute, Frederick, MD 21702, USA.
Zong H; Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China.; Jecho Biopharmaceutical Institute, Shanghai 200240, China.
Yuan Y; Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China.
Wang L; Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China.
Zhang X; Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China.
Ke Y; Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China.
Han L; Jecho Biopharmaceutical Institute, Shanghai 200240, China.
Xu J; School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China.
Ma B; Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China.
Zhang B; Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China.
Zhu J; Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China.; Jecho Biopharmaceutical Institute, Shanghai 200240, China.; Jecho Laboratories, Inc., Frederick, MD 21704, USA.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Jan 27; Vol. 25 (3). Date of Electronic Publication: 2024 Jan 27.
Typ publikacji:
Journal Article
MeSH Terms:
Alzheimer Disease*/metabolism
Alzheimer Disease*/therapy
Amyloidosis*/therapy
Antibodies, Monoclonal, Humanized*/pharmacology
Antibodies, Monoclonal, Humanized*/therapeutic use
Humans ; Amyloid/metabolism ; Amyloid beta-Peptides/immunology ; Amyloid beta-Peptides/metabolism ; Amyloidogenic Proteins/therapeutic use ; Antibodies, Monoclonal/pharmacology ; Antibodies, Monoclonal/therapeutic use ; Peptide Fragments/metabolism
Czasopismo naukowe
Tytuł:
Clinically Important Benefits and Harms of Monoclonal Antibodies Targeting Amyloid for the Treatment of Alzheimer Disease: A Systematic Review and Meta-Analysis.
Autorzy:
Ebell MH; Department of Epidemiology and Biostatistics, College of Public Health, the University of Georgia, Athens, Georgia .
Barry HC; Department of Family Medicine, College of Human Medicine, Michigan State University, East Lansing, Michigan.
Baduni K; Department of Kinesiology, College of Education, the University of Georgia, Athens, Georgia.
Grasso G; Department of Epidemiology and Biostatistics, College of Public Health, the University of Georgia, Athens, Georgia.
Pokaż więcej
Źródło:
Annals of family medicine [Ann Fam Med] 2024 Jan-Feb; Vol. 22 (1), pp. 50-62.
Typ publikacji:
Meta-Analysis; Systematic Review; Journal Article; Review
MeSH Terms:
Alzheimer Disease*/drug therapy
Antibodies, Monoclonal, Humanized*
United States ; Humans ; Antibodies, Monoclonal/therapeutic use ; Mental Status and Dementia Tests ; Edema
Czasopismo naukowe
Tytuł:
Pharmacokinetics and safety of erenumab in pediatric patients with migraine: A phase I, randomized, open-label, multiple-dose study.
Autorzy:
Hershey AD; Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Paiva da Silva Lima G; Amgen Inc., One Amgen Center Drive, Thousand Oaks, California, USA.
Pannacciulli N; Amgen Inc., One Amgen Center Drive, Thousand Oaks, California, USA.
Mackowski M; Amgen Inc., One Amgen Center Drive, Thousand Oaks, California, USA.
Koukakis R; Amgen Inc., Uxbridge, UK.
McVige JW; Dent Neurologic Institute, Amherst, New York, USA.
Pokaż więcej
Źródło:
Clinical and translational science [Clin Transl Sci] 2024 Mar; Vol. 17 (3), pp. e13755.
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Monoclonal, Humanized*/adverse effects
Migraine Disorders*/drug therapy
Adult ; Adolescent ; Humans ; Child ; Double-Blind Method ; Antibodies, Monoclonal/therapeutic use ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer's Disease: A Systematic Review and Network Meta-Analysis.
Autorzy:
Qiao Y; Department of Neurology, Shengjing Hospital of China Medical University, Shenyang, 110000, Liaoning, China.
Gu J; Department of Neurology, Shengjing Hospital of China Medical University, Shenyang, 110000, Liaoning, China.
Yu M; Department of Neurology, Shengjing Hospital of China Medical University, Shenyang, 110000, Liaoning, China.
Chi Y; Department of Neurology, Shengjing Hospital of China Medical University, Shenyang, 110000, Liaoning, China.
Ma Y; Department of Neurology, Shengjing Hospital of China Medical University, Shenyang, 110000, Liaoning, China. .
Pokaż więcej
Źródło:
CNS drugs [CNS Drugs] 2024 Mar; Vol. 38 (3), pp. 169-192. Date of Electronic Publication: 2024 Mar 01.
Typ publikacji:
Meta-Analysis; Systematic Review
MeSH Terms:
Alzheimer Disease*/drug therapy
Cognitive Dysfunction*/drug therapy
Antibodies, Monoclonal, Humanized*
Humans ; Antibodies, Monoclonal/adverse effects ; Network Meta-Analysis ; Activities of Daily Living ; Randomized Controlled Trials as Topic
Raport
Tytuł:
Infections in Children Aged 6 Months to 5 Years Treated with Dupilumab in a Placebo-Controlled Clinical Trial of Moderate-to-Severe Atopic Dermatitis.
Autorzy:
Paller AS; Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.; Ann and Robert H. Lurie Children's Hospital, Chicago, IL, USA.
Siegfried EC; Saint Louis University School of Medicine, St. Louis, MO, USA.; Cardinal Glennon Children's Hospital, St. Louis, MO, USA.
Cork MJ; Sheffield Dermatology Research, University of Sheffield, Sheffield, UK.; Sheffield Children's Hospital, Sheffield, UK.
Arkwright PD; Lydia Becker Institute of Immunology and Inflammation, University of Manchester, Manchester, UK.
Eichenfield LF; Departments of Dermatology and Pediatrics, University of California San Diego, La Jolla, CA, USA.
Ramien M; Division of Dermatology, Department of Medicine, University of Calgary, Calgary, AB, Canada.; Section of Community Pediatrics, Department of Pediatrics, Alberta Children's Hospital, University of Calgary, Calgary, AB, Canada.
Khokhar FA; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.
Chen Z; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.
Zhang A; Sanofi, Cambridge, MA, USA.
Cyr SL; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA. .; Regeneron Pharmaceuticals Inc., 1 Rockwood Road, Sleepy Hollow, NY, 10591, USA. .
Pokaż więcej
Źródło:
Paediatric drugs [Paediatr Drugs] 2024 Mar; Vol. 26 (2), pp. 163-173. Date of Electronic Publication: 2024 Jan 24.
Typ publikacji:
Randomized Controlled Trial; Clinical Trial, Phase III; Journal Article
MeSH Terms:
Dermatitis, Atopic*/drug therapy
Bacterial Infections*/complications
Bacterial Infections*/drug therapy
Antibodies, Monoclonal, Humanized*
Child ; Child, Preschool ; Humans ; Antibodies, Monoclonal/therapeutic use ; Treatment Outcome ; Injections, Subcutaneous ; Severity of Illness Index ; Double-Blind Method
Czasopismo naukowe
Tytuł:
Infliximab-induced psoriasis in an ulcerative colitis patient successfully treated with guselkumab.
Autorzy:
Dai C; Gastroenterology, First Affiliated Hospital. China Medical University, china.
Huang YH; Gastroenterology, First hospital of China Medical University.
Pokaż więcej
Źródło:
Revista espanola de enfermedades digestivas [Rev Esp Enferm Dig] 2024 Mar; Vol. 116 (3), pp. 176-177.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Colitis, Ulcerative*/drug therapy
Colitis, Ulcerative*/chemically induced
Psoriasis*/chemically induced
Psoriasis*/drug therapy
Antibodies, Monoclonal, Humanized*
Humans ; Infliximab/adverse effects ; Antibodies, Monoclonal/adverse effects ; Ustekinumab/therapeutic use ; Interleukin-23/metabolism ; Treatment Outcome ; Severity of Illness Index
Czasopismo naukowe
Tytuł:
Erythrodermic psoriasis treatment with Guselkumab: report of two cases and literature review.
Autorzy:
Welsh E; Welsh Dermatology and Associates, Monterrey Nuevo Leon, Mexico.
Cardenas-de la Garza JA; Rheumatology Departament, Universidad Autónoma de Nuevo León, Hospital Universitario 'Dr José Eleuterio González', Monterrey NL, México. Electronic address: .
García-Lozano JA; Department of Clinical Introduction, Faculty of Medicine and University Hospital 'Dr. José E. González', Autonomous Universitiy of Nuevo León, Monterrey, Nuevo León, Mexico.
Flores-Gutierrez DP; Rheumatology Departament, Universidad Autónoma de Nuevo León, Hospital Universitario 'Dr José Eleuterio González', Monterrey NL, México.
Pokaż więcej
Źródło:
Anais brasileiros de dermatologia [An Bras Dermatol] 2024 Mar-Apr; Vol. 99 (2), pp. 319-320. Date of Electronic Publication: 2023 Dec 07.
Typ publikacji:
Review; Case Reports
MeSH Terms:
Antibodies, Monoclonal, Humanized*/therapeutic use
Psoriasis*/drug therapy
Humans ; Antibodies, Monoclonal ; Severity of Illness Index ; Treatment Outcome ; Double-Blind Method
Recenzja
Tytuł:
Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for ≥ 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial.
Autorzy:
Puig L; Department of Dermatology, IIB Sant Pau, Hospital de Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. .
Costanzo A; Dermatology, Department of Biomedical Sciences, Humanitas University, Milan, Italy.; Humanitas Clinical and Research Center IRCCS, Milan, Italy.
de Jong EMGJ; Department of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands.
Torres T; Centro Hospitalar Universitário do Porto, Porto, Portugal.; Institute of Biomedical Sciences Abel Salazar, University of Porto, Porto, Portugal.
Warren RB; Dermatology Centre, Salford Royal NHS Foundation Trust, National Institute for Health Research Manchester Biomedical Research Centre, The University of Manchester, Manchester, UK.
Wapenaar R; Janssen-Cilag BV, Breda, The Netherlands.
Wegner S; Janssen-Cilag GmbH, Neuss, Germany.
Gorecki P; Janssen-Cilag Ltd, High Wycombe, UK.
Gramiccia T; Janssen-Cilag SpA, Milan, Italy.
Jazra M; Janssen-Cilag, Paris, France.
Buyze J; Janssen Pharmaceutica NV, Beerse, Belgium.
Conrad C; Department of Dermatology, Lausanne University Hospital CHUV and University of Lausanne, Lausanne, Switzerland.
Pokaż więcej
Źródło:
American journal of clinical dermatology [Am J Clin Dermatol] 2024 Mar; Vol. 25 (2), pp. 315-325. Date of Electronic Publication: 2023 Oct 07.
Typ publikacji:
Journal Article
MeSH Terms:
Psoriasis*/diagnosis
Psoriasis*/drug therapy
Biological Products*/therapeutic use
Diabetes Mellitus*/drug therapy
Antibodies, Monoclonal, Humanized*
Humans ; Antibodies, Monoclonal/therapeutic use ; Severity of Illness Index ; Treatment Outcome ; Double-Blind Method
Czasopismo naukowe
Tytuł:
Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells.
Autorzy:
Rajasekaran N; Coherus Biosciences, 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA. .
Wang X; Coherus Biosciences, 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA.
Ravindranathan S; Coherus Biosciences, 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA.
Chin DJ; Coherus Biosciences, 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA.
Tseng SY; Coherus Biosciences, 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA.
Klakamp SL; Coherus Biosciences, 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA.
Widmann K; Coherus Biosciences, 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA.
Kapoor VN; Coherus Biosciences, 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA.
Vexler V; Coherus Biosciences, 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA.
Keegan P; TopAlliance Biosciences, 9430 Key West Ave, Suite 125, Rockville, MD, 20850, USA.
Yao S; TopAlliance Biosciences, 9430 Key West Ave, Suite 125, Rockville, MD, 20850, USA.; Shanghai Junshi Biosciences, Shanghai, China.
LaVallee T; Coherus Biosciences, 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA.
Khare SD; Coherus Biosciences, 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA.
Pokaż więcej
Źródło:
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2024 Feb 24; Vol. 73 (3), pp. 60. Date of Electronic Publication: 2024 Feb 24.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/pathology
Lung Neoplasms*/drug therapy
Esophageal Neoplasms*/drug therapy
Esophageal Squamous Cell Carcinoma*/drug therapy
Nasopharyngeal Neoplasms*
Antibodies, Monoclonal, Humanized*
Humans ; Antibodies, Monoclonal/therapeutic use ; B7-H1 Antigen ; Programmed Cell Death 1 Receptor ; Nasopharyngeal Carcinoma ; T-Lymphocytes/pathology
Czasopismo naukowe
Tytuł:
INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors.
Autorzy:
Hilton JF; The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada.
Ott PA; Dana Farber Cancer Institute, Boston, MA, USA.
Hansen AR; Princess Margaret Cancer Centre, Toronto, ON, Canada.
Li Z; New York University, New York, NY, USA.
Mathew M; Columbia University Irving Medical Center, New York, NY, USA.
Messina CH; GSK, Collegeville, PA, USA.
Dave V; GSK, Bengaluru, Karnataka, India.
Ji X; GSK, Collegeville, PA, USA.
Karpinich NO; GSK, Collegeville, PA, USA.
Hirschfeld S; GSK, Collegeville, PA, USA.
Ballas M; GSK, Collegeville, PA, USA.
Zandberg DP; UPMC Hillman Cancer Center, 5150 Centre Avenue, Pittsburgh, PA, 15232, USA. .
Pokaż więcej
Źródło:
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2024 Feb 13; Vol. 73 (3), pp. 44. Date of Electronic Publication: 2024 Feb 13.
Typ publikacji:
Clinical Trial, Phase II; Clinical Trial, Phase I; Journal Article
MeSH Terms:
Antibodies, Monoclonal, Humanized*/therapeutic use
Head and Neck Neoplasms*
Humans ; Antibodies, Monoclonal/therapeutic use ; Immunotherapy
Czasopismo naukowe
Tytuł:
A monoclonal antibody targeting a large surface of the receptor binding motif shows pan-neutralizing SARS-CoV-2 activity.
Autorzy:
de Campos-Mata L; Translational Clinical Research Program, Hospital del Mar Research Institute (IMIM), Barcelona, Spain.; Division of Immunology, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden.
Trinité B; IrsiCaixa AIDS Research Institute, Hospital Germans Trias I Pujol, Campus Can Ruti, Badalona, Spain.
Modrego A; Centro Nacional de Biotecnología (CNB-CSIC), Madrid, Spain.
Tejedor Vaquero S; Translational Clinical Research Program, Hospital del Mar Research Institute (IMIM), Barcelona, Spain.
Pradenas E; IrsiCaixa AIDS Research Institute, Hospital Germans Trias I Pujol, Campus Can Ruti, Badalona, Spain.
Pons-Grífols A; IrsiCaixa AIDS Research Institute, Hospital Germans Trias I Pujol, Campus Can Ruti, Badalona, Spain.
Rodrigo Melero N; Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain.
Carlero D; Centro Nacional de Biotecnología (CNB-CSIC), Madrid, Spain.
Marfil S; IrsiCaixa AIDS Research Institute, Hospital Germans Trias I Pujol, Campus Can Ruti, Badalona, Spain.
Santiago C; Centro Nacional de Biotecnología (CNB-CSIC), Madrid, Spain.
Raïch-Regué D; IrsiCaixa AIDS Research Institute, Hospital Germans Trias I Pujol, Campus Can Ruti, Badalona, Spain.
Bueno-Carrasco MT; Centro Nacional de Biotecnología (CNB-CSIC), Madrid, Spain.
Tarrés-Freixas F; IrsiCaixa AIDS Research Institute, Hospital Germans Trias I Pujol, Campus Can Ruti, Badalona, Spain.; IRTA. Programa de Sanitat Animal. Centre de Recerca en Sanitat Animal (CReSA), Campus de la Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain.
Abancó F; IrsiCaixa AIDS Research Institute, Hospital Germans Trias I Pujol, Campus Can Ruti, Badalona, Spain.
Urrea V; IrsiCaixa AIDS Research Institute, Hospital Germans Trias I Pujol, Campus Can Ruti, Badalona, Spain.
Izquierdo-Useros N; IrsiCaixa AIDS Research Institute, Hospital Germans Trias I Pujol, Campus Can Ruti, Badalona, Spain.; CIBERINFEC, ISCIII, Madrid, Spain.
Riveira-Muñoz E; IrsiCaixa AIDS Research Institute, Hospital Germans Trias I Pujol, Campus Can Ruti, Badalona, Spain.
Ballana E; IrsiCaixa AIDS Research Institute, Hospital Germans Trias I Pujol, Campus Can Ruti, Badalona, Spain.; CIBERINFEC, ISCIII, Madrid, Spain.; Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, Badalona, Spain.
Pérez M; Unitat Mixta d'Investigació IRTA-UAB en Sanitat Animal. Centre de Recerca en Sanitat Animal (CReSA), Campus de la Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain.; IRTA. Programa de Sanitat Animal. Centre de Recerca en Sanitat Animal (CReSA), Campus de la Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain.
Vergara-Alert J; Unitat Mixta d'Investigació IRTA-UAB en Sanitat Animal. Centre de Recerca en Sanitat Animal (CReSA), Campus de la Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain.; IRTA. Programa de Sanitat Animal. Centre de Recerca en Sanitat Animal (CReSA), Campus de la Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain.
Segalés J; Unitat Mixta d'Investigació IRTA-UAB en Sanitat Animal. Centre de Recerca en Sanitat Animal (CReSA), Campus de la Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain.; Departament de Sanitat i Anatomia Animals, Facultat de Veterinària, Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain.
Carolis C; Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain. .
Arranz R; Centro Nacional de Biotecnología (CNB-CSIC), Madrid, Spain. .
Blanco J; IrsiCaixa AIDS Research Institute, Hospital Germans Trias I Pujol, Campus Can Ruti, Badalona, Spain. .; CIBERINFEC, ISCIII, Madrid, Spain. .; Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, Badalona, Spain. .; Infectious Diseases and Immunity, Faculty of Medicine, University of Vic-Central University of Catalonia (UVic-UCC), Barcelona, Spain. .
Magri G; Translational Clinical Research Program, Hospital del Mar Research Institute (IMIM), Barcelona, Spain. .; Immunology Unit, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain. .
Pokaż więcej
Źródło:
Nature communications [Nat Commun] 2024 Feb 05; Vol. 15 (1), pp. 1051. Date of Electronic Publication: 2024 Feb 05.
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Monoclonal*
COVID-19*
Humans ; Animals ; Mice ; SARS-CoV-2 ; Cryoelectron Microscopy ; Antibodies, Monoclonal, Humanized ; Antibodies, Neutralizing ; Antibodies, Viral ; Spike Glycoprotein, Coronavirus/genetics
SCR Organism:
SARS-CoV-2 variants
Czasopismo naukowe
Tytuł:
Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors.
Autorzy:
Robbrecht D; Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Grob JJ; Dermatology and Oncology Service, Aix Marseille University and Timone Hospital, Marseille, France.
Bechter O; Department of General Medical Oncology, Leuven Cancer Institute, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
Simonelli M; Department of Biomedical Science, Humanitas University, Milan, Italy.; Department of Medical Oncology and Hematology, IRCCS Humanitas Research Hospital, Milan, Italy.
Doger B; START Madrid-FJD, Early Phase Clinical Trials Unit, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
Borbath I; Department of Hepatogastroenterology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.
Butler MO; Department of Medical Oncology and Hematology, Department of Immunology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
Cheng T; Division of Medical Oncology, Department of Oncology, University of Calgary, Calgary, Alberta, Canada.
Romano PM; Département d'Innovation Thérapeutique et d'Essais Précoces, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Pons-Tostivint E; Service d'oncologie médicale, CHU Nantes, Université de Nantes, Nantes, France.
Di Nicola M; Unit of Immunotherapy and Anticancer Innovative Therapeutics, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Curigliano G; Division of Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Ryu MH; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Rodriguez-Vida A; Medical Oncology Department, Hospital del Mar, CIBERONC, IMIM Research Institute, Barcelona, Spain.
Schadendorf D; Department of Dermatology, University Hospital Essen, Essen, Germany.; German Cancer Consortium, partner site Essen, Essen, Germany.; NCT-West, Campus Essen, Essen, Germany.; University Alliance Ruhr, Research Center One Health, University Duisburg-Essen, Essen, Germany.
Garralda E; Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology, Barcelona, Spain.
Abbadessa G; Sanofi, Bridgewater, New Jersey, USA.
Demers B; Sanofi, Vitry-Sur-Seine, France.
Amrate A; Sanofi, Vitry-Sur-Seine, France.
Wang H; Sanofi, Cambridge, Massachusetts, USA.
Lee JS; Sanofi, Cambridge, Massachusetts, USA.
Pomponio R; Sanofi, Cambridge, Massachusetts, USA.
Wang R; Sanofi, Cambridge, Massachusetts, USA.
Pokaż więcej
Źródło:
Clinical and translational science [Clin Transl Sci] 2024 Feb; Vol. 17 (2), pp. e13736.
Typ publikacji:
Clinical Trial, Phase I; Journal Article
MeSH Terms:
Antibodies, Monoclonal, Humanized*
Antineoplastic Agents*/adverse effects
Antineoplastic Agents*/therapeutic use
Melanoma*/drug therapy
Humans ; Antibodies, Monoclonal/therapeutic use ; Biomarkers ; Transforming Growth Factor beta/antagonists & inhibitors ; Transforming Growth Factors/therapeutic use
Czasopismo naukowe
Tytuł:
Real-world data of Brazilian adults with X-linked hypophosphatemia (XLH) treated with burosumab and comparison with other worldwide cohorts.
Autorzy:
Vaisbich MH; University of São Paulo School of Medicine, Sao Paulo, Brazil.
de Cillo ACP; Pontifícia Universidade Católica, Campinas, Brazil.
Silva BCC; Hospital Felício Rocho, Osteometabolism Unit of Santa Casa de Belo Horizonte, Professor of Medicine at University Center of Belo Horizonte - UNIBH, Belo Horizonte, Brazil.
DÁlva CB; Federal University of Ceará, Fortaleza, Brazil.
de Carvalho ÉH; Instituto de Medicina Integrada Professor Fernado Figueira, recife, Federal University of Pernambuco, Recife, Brazil.
de Almeida JMCM; Federal University of Pernambuco, Recife, Brazil.
Marques LLM; Medical Student Federal University of Parana, Curitiba, Brazil.
Ribeiro M; Genetic Unit of Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
da Silva MBM; Endocrinology Unit of Santa Casa de São Paulo School of Medicine, São Paulo, Brazil.
de Medeiros PFV; Federal University of Campina Grande, Campina Grande, Brazil.
Mendes PH; Orthopedic Unit at Instituto Fernandes Figueira, Rio de Janeiro, Brazil.
Pokaż więcej
Źródło:
Molecular genetics & genomic medicine [Mol Genet Genomic Med] 2024 Feb; Vol. 12 (2), pp. e2387.
Typ publikacji:
Journal Article
MeSH Terms:
Familial Hypophosphatemic Rickets*/drug therapy
Familial Hypophosphatemic Rickets*/genetics
Antibodies, Monoclonal, Humanized*
Adult ; Humans ; Antibodies, Monoclonal/therapeutic use ; Brazil ; Fibroblast Growth Factors/genetics ; Fibroblast Growth Factors/metabolism ; Phosphates/therapeutic use
Czasopismo naukowe
Tytuł:
Applying a cost-based pricing model for innovative cancer treatments subject to indication expansion: A case study for pembrolizumab and daratumumab.
Autorzy:
Heine RJSD; Erasmus School of Health Policy and Management (ESHPM), Erasmus University Rotterdam, Rotterdam, The Netherlands.; Erasmus Centre for Health Economics Rotterdam (EsCHER), Erasmus University Rotterdam, Rotterdam, The Netherlands.
Thielen FW; Erasmus School of Health Policy and Management (ESHPM), Erasmus University Rotterdam, Rotterdam, The Netherlands.; Erasmus Centre for Health Economics Rotterdam (EsCHER), Erasmus University Rotterdam, Rotterdam, The Netherlands.
Mathijssen RHJ; Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, Rotterdam, The Netherlands.
van Leeuwen RWF; Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, Rotterdam, The Netherlands.; Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, Rotterdam, The Netherlands.
Franken MG; Erasmus School of Health Policy and Management (ESHPM), Erasmus University Rotterdam, Rotterdam, The Netherlands.; Erasmus Centre for Health Economics Rotterdam (EsCHER), Erasmus University Rotterdam, Rotterdam, The Netherlands.
Uyl-de Groot CA; Erasmus School of Health Policy and Management (ESHPM), Erasmus University Rotterdam, Rotterdam, The Netherlands.; Erasmus Centre for Health Economics Rotterdam (EsCHER), Erasmus University Rotterdam, Rotterdam, The Netherlands.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2024 Feb 01; Vol. 19 (2), pp. e0293264. Date of Electronic Publication: 2024 Feb 01 (Print Publication: 2024).
Typ publikacji:
Journal Article
MeSH Terms:
Drug Costs*
Neoplasms*/drug therapy
Antibodies, Monoclonal, Humanized*
Humans ; Antibodies, Monoclonal/therapeutic use ; Cost Control
Czasopismo naukowe
Tytuł:
Passive immunotherapy for Alzheimer's disease.
Autorzy:
Guo X; Center for Brain Sciences, the First Affiliated Hospital of Xiamen University, Institute of Neuroscience, Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, School of Medicine, Xiamen University, Xiamen, Fujian 361005, China.
Yan L; School of Traditional Chinese Medicine, Jinan University, 601 Huangpu Avenue West, Guangzhou, Guangdong 510632, China.
Zhang D; Center for Brain Sciences, the First Affiliated Hospital of Xiamen University, Institute of Neuroscience, Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, School of Medicine, Xiamen University, Xiamen, Fujian 361005, China.
Zhao Y; Center for Brain Sciences, the First Affiliated Hospital of Xiamen University, Institute of Neuroscience, Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, School of Medicine, Xiamen University, Xiamen, Fujian 361005, China. Electronic address: .
Pokaż więcej
Źródło:
Ageing research reviews [Ageing Res Rev] 2024 Feb; Vol. 94, pp. 102192. Date of Electronic Publication: 2024 Jan 14.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Alzheimer Disease*/drug therapy
Neurodegenerative Diseases*/drug therapy
Antibodies, Monoclonal, Humanized*
Humans ; Amyloid beta-Peptides ; Antibodies, Monoclonal/therapeutic use ; Immunization, Passive ; Immunotherapy ; tau Proteins
Czasopismo naukowe
Tytuł:
Nonsynonymous mutations in VEGF receptor binding domain alter the efficacy of bevacizumab treatment.
Autorzy:
Ahamed A; Department of Zoology, Netaji Subhas Open University, West Bengal, India.
Samanta A; Applied Biochemistry Laboratory, Department of Biological Sciences, Aliah University, Kolkata, India.
Alam SSM; Applied Biochemistry Laboratory, Department of Biological Sciences, Aliah University, Kolkata, India.
Mir SA; School of Life Sciences, Sambalpur University, Jyoti Vihar, Odisha, India.
Jamil Z; Applied Biochemistry Laboratory, Department of Biological Sciences, Aliah University, Kolkata, India.
Ali S; Clinical and Applied Genomics (CAG) Laboratory, Department of Biological Sciences, Aliah University, Kolkata, India.
Hoque M; Applied Biochemistry Laboratory, Department of Biological Sciences, Aliah University, Kolkata, India.
Pokaż więcej
Źródło:
Journal of cellular biochemistry [J Cell Biochem] 2024 Feb; Vol. 125 (2), pp. e30515. Date of Electronic Publication: 2024 Jan 11.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Vascular Endothelial Growth Factor A*/metabolism
Antibodies, Monoclonal, Humanized*
Bevacizumab/pharmacology ; Bevacizumab/therapeutic use ; Molecular Docking Simulation ; Antibodies, Monoclonal/pharmacology ; Receptors, Vascular Endothelial Growth Factor/genetics ; Protein Isoforms ; Mutation ; Angiogenesis Inhibitors/pharmacology ; Angiogenesis Inhibitors/therapeutic use
Czasopismo naukowe
Tytuł:
Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-Up.
Autorzy:
Ho C; Department of Internal Medicine, Division of Hematology and Oncology, University of Washington, Seattle, WA; Fred Hutchinson Cancer Center, Seattle, WA. Electronic address: .
Gopal AK; Department of Internal Medicine, Division of Hematology and Oncology, University of Washington, Seattle, WA; Fred Hutchinson Cancer Center, Seattle, WA.
Till BG; Department of Internal Medicine, Division of Hematology and Oncology, University of Washington, Seattle, WA; Fred Hutchinson Cancer Center, Seattle, WA.
Shadman M; Department of Internal Medicine, Division of Hematology and Oncology, University of Washington, Seattle, WA; Fred Hutchinson Cancer Center, Seattle, WA.
Lynch RC; Department of Internal Medicine, Division of Hematology and Oncology, University of Washington, Seattle, WA; Fred Hutchinson Cancer Center, Seattle, WA.
Cowan AJ; Department of Internal Medicine, Division of Hematology and Oncology, University of Washington, Seattle, WA; Fred Hutchinson Cancer Center, Seattle, WA.
Wu QV; Fred Hutchinson Cancer Center, Seattle, WA.
Voutsinas J; Fred Hutchinson Cancer Center, Seattle, WA.
Rasmussen HA; Department of Internal Medicine, Division of Hematology and Oncology, University of Washington, Seattle, WA.
Blue K; Department of Internal Medicine, Division of Hematology and Oncology, University of Washington, Seattle, WA.
Ujjani CS; Department of Internal Medicine, Division of Hematology and Oncology, University of Washington, Seattle, WA; Fred Hutchinson Cancer Center, Seattle, WA.
Cassaday RD; Department of Internal Medicine, Division of Hematology and Oncology, University of Washington, Seattle, WA; Fred Hutchinson Cancer Center, Seattle, WA.
Fromm JR; Department of Laboratory Medicine, Division of Hematopathology, University of Washington, Seattle, WA.
Fang M; Fred Hutchinson Cancer Center, Seattle, WA.
Smith SD; Department of Internal Medicine, Division of Hematology and Oncology, University of Washington, Seattle, WA; Fred Hutchinson Cancer Center, Seattle, WA.
Pokaż więcej
Źródło:
Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2024 Feb; Vol. 24 (2), pp. e33-e39.e1. Date of Electronic Publication: 2023 Oct 18.
Typ publikacji:
Journal Article
MeSH Terms:
B7-H1 Antigen*
Lymphoma, Large B-Cell, Diffuse*
Antibodies, Monoclonal, Humanized*
Adult ; Humans ; Rituximab/adverse effects ; Vincristine/adverse effects ; Prednisone/adverse effects ; Follow-Up Studies ; Antibodies, Monoclonal, Murine-Derived/adverse effects ; Cyclophosphamide/adverse effects ; Doxorubicin/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects
Czasopismo naukowe
Tytuł:
Real-world effectiveness and safety of evolocumab in very high-risk atherosclerotic cardiovascular disease patients with acute ischemic stroke.
Autorzy:
Zhang T; Department of Neurology, Tianjin Key Laboratory of Cerebrovascular and Neurodegenerative Diseases, Clinical College of Neurology, Neurosurgery and Neurorehabilitation, Tianjin Huanhu Hospital, Tianjin Medical University, Tianjin, 300350, China.
Zhang Y; Department of Neurology, Tianjin Key Laboratory of Cerebrovascular and Neurodegenerative Diseases, Clinical College of Neurology, Neurosurgery and Neurorehabilitation, Tianjin Huanhu Hospital, Tianjin Medical University, Tianjin, 300350, China.
Yang Y; Department of Neurology, Tianjin Key Laboratory of Cerebrovascular and Neurodegenerative Diseases, Clinical College of Neurology, Neurosurgery and Neurorehabilitation, Tianjin Huanhu Hospital, Tianjin Medical University, Tianjin, 300350, China.
Liao H; Department of Neurology, Tianjin Key Laboratory of Cerebrovascular and Neurodegenerative Diseases, Clinical College of Neurology, Neurosurgery and Neurorehabilitation, Tianjin Huanhu Hospital, Tianjin Medical University, Tianjin, 300350, China.
Li X; Department of Neurology, Tianjin Key Laboratory of Cerebrovascular and Neurodegenerative Diseases, Clinical College of Neurology, Neurosurgery and Neurorehabilitation, Tianjin Huanhu Hospital, Tianjin Medical University, Tianjin, 300350, China.
Liu R; Department of Neurology, Tianjin Key Laboratory of Cerebrovascular and Neurodegenerative Diseases, Clinical College of Neurology, Neurosurgery and Neurorehabilitation, Tianjin Huanhu Hospital, Tianjin Medical University, Tianjin, 300350, China.
Liu X; Department of Neurology, Tianjin Key Laboratory of Cerebrovascular and Neurodegenerative Diseases, Clinical College of Neurology, Neurosurgery and Neurorehabilitation, Tianjin Huanhu Hospital, Tianjin Medical University, Tianjin, 300350, China.
Yang L; Department of Neurology, Tianjin Key Laboratory of Cerebrovascular and Neurodegenerative Diseases, Clinical College of Neurology, Neurosurgery and Neurorehabilitation, Tianjin Huanhu Hospital, Tianjin Medical University, Tianjin, 300350, China.
Yue W; Department of Neurology, Tianjin Key Laboratory of Cerebrovascular and Neurodegenerative Diseases, Clinical College of Neurology, Neurosurgery and Neurorehabilitation, Tianjin Huanhu Hospital, Tianjin Medical University, Tianjin, 300350, China. .
Pokaż więcej
Źródło:
Journal of thrombosis and thrombolysis [J Thromb Thrombolysis] 2024 Feb; Vol. 57 (2), pp. 302-311. Date of Electronic Publication: 2023 Dec 08.
Typ publikacji:
Journal Article
MeSH Terms:
Hydroxymethylglutaryl-CoA Reductase Inhibitors*/therapeutic use
Anticholesteremic Agents*/adverse effects
Ischemic Stroke*/drug therapy
Cardiovascular Diseases*/drug therapy
Atherosclerosis*/drug therapy
Antibodies, Monoclonal, Humanized*
Humans ; Cholesterol, LDL ; Retrospective Studies ; Antibodies, Monoclonal/adverse effects ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Combination treatment with monoclonal antibodies: Dupilumab and ustekinumab for the treatment of severe atopic dermatitis and Crohn disease.
Autorzy:
Alegre-Bailo A; Dermatology Department of the Rey Juan Carlos Hospital, Móstoles, Madrid, Spain.
Sánchez-Gilo A; Dermatology Department of the Rey Juan Carlos Hospital, Móstoles, Madrid, Spain.
Gonzalo González I; Dermatology Department of the Infanta Elena Hospital, Valdemoro, Madrid, Spain.
Vicente Martín FJ; Dermatology Department of the Rey Juan Carlos Hospital, Móstoles, Madrid, Spain.
Pokaż więcej
Źródło:
The Australasian journal of dermatology [Australas J Dermatol] 2024 Feb; Vol. 65 (1), pp. 63-66. Date of Electronic Publication: 2023 Nov 06.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Dermatitis, Atopic*/drug therapy
Crohn Disease*/drug therapy
Antibodies, Monoclonal, Humanized*
Humans ; Antibodies, Monoclonal/therapeutic use ; Ustekinumab/therapeutic use ; Treatment Outcome ; Severity of Illness Index
Czasopismo naukowe
Tytuł:
Avelumab treatment for patients with metastatic Merkel cell carcinoma can be safely stopped after 1 year and a PET/CT-confirmed complete response.
Autorzy:
Zijlker LP; Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
Levy S; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Wolters W; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
van Thienen JV; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
van Akkooi ACJ; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
Tesselaar MET; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Pokaż więcej
Źródło:
Cancer [Cancer] 2024 Feb 01; Vol. 130 (3), pp. 433-438. Date of Electronic Publication: 2023 Oct 03.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Merkel Cell*/diagnostic imaging
Carcinoma, Merkel Cell*/drug therapy
Carcinoma, Merkel Cell*/chemically induced
Skin Neoplasms*/diagnostic imaging
Skin Neoplasms*/drug therapy
Skin Neoplasms*/chemically induced
Antibodies, Monoclonal, Humanized*
Humans ; Positron Emission Tomography Computed Tomography ; Fluorodeoxyglucose F18 ; Antibodies, Monoclonal/adverse effects
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies